STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink tumors and reduce radiation side effects in young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to improve …
Matched conditions: STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Could less radiation be just as effective for this head and neck cancer?
Disease control Recruiting nowThis study looks at whether giving lower doses of radiation after a good response to initial chemotherapy can control EBV-associated nasopharyngeal cancer as well as standard radiation. About 66 people with stage III or IVA disease will receive either reduced or standard radiatio…
Matched conditions: STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New drug aims to prevent painful mouth sores in head and neck cancer treatment
Symptom relief Recruiting nowThis phase 2 trial tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medication. The goal is t…
Matched conditions: STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer do or don't follow swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the illness affect exercise habits. The goal is to learn what h…
Matched conditions: STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC